Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Verma S, et al. Among authors: gilbert re. Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22. Circulation. 2019. PMID: 31434508 Clinical Trial.
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, Zuo F, Mistry N, Thorpe KE, Goldenberg RM, Yan AT, Connelly KA, Verma S. Mazer CD, et al. Among authors: gilbert re. Circulation. 2020 Feb 25;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707794 No abstract available.
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho E, Zahrani M, Garg V, Zuo F, Teoh H, Quan A, Leiter LA, Gilbert RE, Zinman B, Thorpe KE, Jüni P, Mazer CD, Verma S, Ong G, Connelly KA. Bami K, et al. Among authors: gilbert re. J Am Soc Echocardiogr. 2020 May;33(5):644-646. doi: 10.1016/j.echo.2020.02.005. Epub 2020 Mar 18. J Am Soc Echocardiogr. 2020. PMID: 32199780 Clinical Trial. No abstract available.
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Mason T, Coelho-Filho OR, Verma S, Chowdhury B, Zuo F, Quan A, Thorpe KE, Bonneau C, Teoh H, Gilbert RE, Leiter LA, Jüni P, Zinman B, Jerosch-Herold M, Mazer CD, Yan AT, Connelly KA. Mason T, et al. Among authors: gilbert re. JACC Cardiovasc Imaging. 2021 Jun;14(6):1164-1173. doi: 10.1016/j.jcmg.2020.10.017. Epub 2021 Jan 13. JACC Cardiovasc Imaging. 2021. PMID: 33454272 Free article. Clinical Trial.
Understanding EMPA-REG OUTCOME.
Gilbert RE, Connelly KA. Gilbert RE, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):930-1. doi: 10.1016/S2213-8587(15)00427-1. Lancet Diabetes Endocrinol. 2015. PMID: 26590681 No abstract available.
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
Opingari E, Verma S, Connelly KA, Mazer CD, Teoh H, Quan A, Zuo F, Pan Y, Bhatt DL, Zinman B, Leiter LA, Yan AT, Cherney DZI, Gilbert RE. Opingari E, et al. Among authors: gilbert re. Nephrol Dial Transplant. 2020 May 1;35(5):895-897. doi: 10.1093/ndt/gfz294. Nephrol Dial Transplant. 2020. PMID: 32159783 No abstract available.
339 results